• Explore /
  • Poster
  • / Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).

Acalabrutinib alone or in combination with rituximab (R) in follicular lymphoma (FL).

Abstract Poster

Authors

null

Nathan Hale Fowler

The University of Texas MD Anderson Cancer Center, Houston, TX

Nathan Hale Fowler , Morton Coleman , Don A. Stevens , Sonali M. Smith , Parameswaran Venugopal , Peter Martin , Tycel Jovelle Phillips , Richy Agajanian , Deborah Marie Stephens , Raquel Izumi , Jean Cheung , J. Greg Slatter , Ming Yin , Minoti Hiremath , Naomi N. H. Hunder , Beth Christian

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2018 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Track

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Sub Track

Non-Hodgkin Lymphoma

Clinical Trial Registration Number

NCT02180711

Citation

J Clin Oncol 36, 2018 (suppl; abstr 7549)

DOI

10.1200/JCO.2018.36.15_suppl.7549

Abstract #

7549

Poster Bd #

186

Abstract Disclosures

Similar Posters

First Author: Martin JS Dyer

First Author: Connie Lee Batlevi

First Author: Thomas Lillie

Poster

2024 ASCO Annual Meeting

A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.

A phase I dose escalation trial of BCD-145 in patients with unresectable or metastatic melanoma.

First Author: Fedor Kryukov